Step-up approach for surgical treatment of the spinal canal stenosis in a patient with mucopolysaccharidosis type VI (Maroto–Lami syndrome)

Abstract

The article presents a clinical case of step-up surgical treatment of spinal canal stenosis at the craniovertebral and thoracolumbar level in a patient with mucopolysaccharidosis (MPS) type VI. The treatment method gives an opportunity to achieve a satisfactory result at the background of severe metabolic disease.

Keywords

mucopolysaccharidosis / craniovertebral stenosis / thoracolumbar kyphosis

References

[1] Whitley CB, Belani KG, Chang PN, et al. Long-term outcome of Hurler syndrome following bone marrow transplantation. Am J Med Genet. 1993;46(2):209–218. doi: 10.1002/ajmg.1320460222

[2] Alonzo-Rojo A, Garcia-Ortiz JE, Ortiz-Aranda M, et al. Clinical features of Mexican patients with Mucopolysaccharidosis type I. Genet Mol Res. 2017;16(3):1–8. doi: 10.4238/gmr16032602

[3] Giugliani R, Federhen A, Rojas MVM, et al. Mucopolysaccharidosis I, II, and VI: Brief review and guidelines for treatment. Genet Mol Biol. 2010;33(4):589–604. doi: 10.1590/S1415-47572010005000093

[4] Moore D, Connock MJ, Wraith E, Lavery C. The prevalence of and survival in Mucopolysaccharidosis I: Hurler, Hurler-Scheie and Scheie syndromes in the UK. Orphanet J Rare Dis. 2008;3:24. doi: 10.1186/1750-1172-3-24

[5] Khan SA, Peracha H, Ballhausen D, et al. Epidemiology of mucopolysaccharidoses. Mol Genet Metab. 2017;121(3):227–240. doi: 10.1016/j.ymgme.2017.05.016

[6] Alden TD, Amartino HH, Dalla Corte A, et al. Surgical Management of Neurological Manifestations of Mucopolysaccharidosis Disorders. Vol 122S. United States: Elsevier Inc; 2017. doi: 10.1016/j.ymgme.2017.09.011

[7] Williams N, Cundy PJ, Eastwod DM. Surgical Management of Thoracolumbar Kyphosis in Patients with Mucopolysaccharidosis. Spine (Phila Pa 1976). 2017;42(23):1817–1825. doi: 10.1097/BRS.0000000000002242

[8] Tandon V, Williamson JB, Cowie RA, Wraith JE. Spinal problems in mucopolysaccharidosis I (Hurler syndrome). J Bone Joint Surg Br. 1996;78(6):938–944.

[9] Borlot F, Arantes PR, Quaio CR, et al. Mucopolysaccharidosis type IVA: Evidence of primary and secondary central nervous system involvement. Am J Med Genet Part A. 2014;164(5):1162–1169. doi: 10.1002/ajmg.a.36424

[10] Kachur E, Del Maestro R. Mucopolysaccharidoses and spinal cord compression: case report and review of the literature with implications of bone marrow transplantation. Neurosurgery. 2000;47(1):223–229.

[11] Bradley WGJ, Scalzo D, Queralt J, et al. Normal-pressure hydrocephalus: evaluation with cerebrospinal fluid flow measurements at MR imaging. Radiology. 1996;198(2):523–529. doi: 10.1148/radiology.198.2.8596861

[12] Stoquart-Elsankari S, Lehmann P, Villette A, et al. A phase-contrast MRI study of physiologic cerebral venous flow. J Cereb Blood Flow Metab. 2009;29(6):1208–1215. doi: 10.1038/jcbfm.2009.29

[13] Charrow J, Alden TD, Breathnach CAR, et al. Diagnostic evaluation, monitoring, and perioperative management of spinal cord compression in patients with Morquio syndrome. Mol Genet Metab. 2015;114(1):11–18. doi: 10.1016/j.ymgme.2014.10.010

[14] Lampe C, Lampe C, Schwarz M, et al. Craniocervical decompression in patients with mucopolysaccharidosis VI: Development of a scoring system to determine indication and outcome of surgery. J Inherit Metab Dis. 2013;36(6):1005–1013. doi: 10.1007/s10545-013-9591-5

[15] Kolesov SV, Mikhaylova LK, Kolbovsky DA, Pereverzev VS. Surgical Treatment of Cervical Stenosis in Patients With Mucopolysaccharidosis: Systematic Review. Traumatol Orthop Russ. 2018;24(2):127–137. doi: 10.21823/2311-2905-2018-24-2-127-137

[16] Mut M, Cila A, Varli K, Akalan N. Multilevel myelopathy in Maroteaux-Lamy syndrome and review of the literature. Clin Neurol Neurosurg. 2005;107(3):230–235. doi: 10.1016/j.clineuro.2004.05.003

[17] Lee C, Dineen TE, Brack M, et al. The mucopolysaccharidoses: characterization by cranial MR imaging. AJNR Am J Neuroradiol. 1993;14(6):1285–1292.

[18] Hendriksz CJ, Berger KI, Giugliani R, et al. International guidelines for the management and treatment of Morquio a syndrome. Am J Med Genet Part A. 2015;167(1):11–25. doi: 10.1002/ajmg.a.36833

[19] Al Sawaf S, Mayatepek E, Hoffmann B. Neurological findings in Hunter disease: Pathology and possible therapeutic effects reviewed. J Inherit Metab Dis. 2008;31(4):473–480. doi: 10.1007/s10545-008-0878-x

[20] Dalla-Corte A, Souza CFM, Vairo F, et al. An algorithm to assess the need for CSF shunting in mucopolysaccharidosis patients. Mol Genet Metab. 2018;120(1):S39. doi: 10.1016/j.ymgme.2016.11.075

[21] Mikhailova LK, Kuleshov AA, Arzhakova NI, et al. Maroteaux-Lamy syndrome–mucopolysaccharidosis type VI: a case report (errors and complications). Genij Ortop. 2017;23(1):80–84. doi:10.18019/1028-4427-2017-23-1-80-84

[22] Semenza GL, Pyeritz RE. Respiratory complications of mucopolysaccharide storage disorders. Medicine (Baltimore). 1988;67(4):209–219.

[23] Muhlebach MS, Shaffer CB, Georges L, et al. Bronchoscopy and airway management in patients with mucopolysaccharidoses (MPS). Pediatr Pulmonol. 2013;48(6):601–607. doi: 10.1002/ppul.22629

[24] Munoz-Rojas M-V, Vieira T, Costa R, et al. Intrathecal enzyme replacement therapy in a patient with mucopolysaccharidosis type I and symptomatic spinal cord compression. Am J Med Genet A. 2008;146A(19):2538–2544. doi:10.1002/ajmg.a.32294

[25] Muenzer J, Hendriksz CJ, Fan Z, et al. A phase I/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II. Genet Med. 2016;18(1):73–81. doi: 10.1038/gim.2015.36

[26] Muenzer J. Overview of the mucopolysaccharidoses. Rheumatology. 2011;50(SUPPL. 5). doi: 10.1093/rheumatology/ker394

RIGHTS & PERMISSIONS

Eco-Vector